Always approachable and easy to talk to.
Always fair, kind, and deeply insightful.
Encourages deep understanding and curiosity.
Always supportive and understanding.
Always goes the extra mile for students.
Shalini Arunogiri, MBBS (Hons), PhD, FRANZCP (Cert. Addiction Psychiatry), MPsychiatry, MSc (Addiction Studies), is an Associate Professor (Research) at Turning Point and an NHMRC Emerging Leader Research Fellow at the Monash Addiction Research Centre, Eastern Health Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University. As a clinical addiction psychiatrist, she possesses extensive experience working across alcohol and other drug (AOD) and mental health services. She serves as Clinical Director of the Statewide Centre for Addiction and Mental Health at Turning Point and was the inaugural Clinical Director of the Hamilton Centre, Victoria's statewide service for treatment, research, and training in integrated care for mental health and addiction. She has also served as Deputy Head of the Department of Psychiatry, Central Clinical School, Monash University.
Arunogiri's research specializations encompass methamphetamine use disorder, co-occurring mental health and substance use disorders (dual diagnosis) and integrated care, management of co-occurring PTSD/trauma and addiction, psychedelic-assisted therapy for addiction and co-occurring mental health disorders, women's health and addiction, and clinical trials and interventions for addiction. She has authored over 50 peer-reviewed publications, book chapters, and technical reports, including "Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial" (2024), "Emotion Recognition and Impulsive Choice in Relation to Methamphetamine Use and Psychosis Symptoms" (2019), "Mental health outcomes associated with the use of amphetamines" (2020), and "Zero alcohol, but not zero risk?" (2024). Her awards include the NHMRC Emerging Leadership Fellowship and the CPDD NIDA Women & Sex/Gender Junior Investigator Travel Award (2020). Arunogiri exerts considerable influence in the field through leadership positions such as Chair of the RANZCP Faculty of Addiction Psychiatry (2017-2024), Board of Directors for the International Society of Addiction Medicine (2019-2024), executive committee member of the World Association of Dual Disorders, and Board Director for the Foundation for Alcohol Research and Education. She mentors health professionals advancing their research careers and advocates for clinician-researchers in mental health and addiction.
Explore how GLP-1 drugs like Ozempic may lower addiction risks, with insights from a landmark BMJ study and Australian university research at Monash, Florey, and Griffith.
Photo by Markus Winkler on Unsplash
Photo by Osarugue Igbinoba on Unsplash
Photo by MAK on Unsplash
Photo by Sasun Bughdaryan on Unsplash
Photo by Wolfgang Hasselmann on Unsplash
Photo by Rémi Rivière on Unsplash
Photo by Markus Spiske on Unsplash
Have a story or a research paper to share? Become a contributor and publish your work on AcademicJobs.com.
Submit your Research - Make it Global News
